Supercomputer Simulations Present Potential Active Substances Against Coronavirus

Several drugs approved for treating hepatitis C viral infection were identified as potential candidates against COVID-19, a new disease caused by the SARS-CoV-2 coronavirus. This is the result of research based on extensive calculations using the MOGON II supercomputer at Johannes Gutenberg University Mainz (JGU). One of the most powerful computers in the world,

MOGON II is operated by JGU and the Helmholtz Institute Mainz. As the JGU researchers explained in their paper recently published at the World Health Organization (WHO) website, they had simulated the way that about 42,000 different substances listed in open databases bind to certain proteins of SARS-CoV-2 and thereby inhibit the penetration of the virus into the human body or its multiplication. "This computer simulation method is known as molecular docking and it has been recognized and used for years. It is much faster and less expensive than lab experiments," said Professor Thomas Efferth of the JGU Institute of Pharmacy and Biomedical Sciences, lead author of the study. "As far as we know, we were the first to have used molecular docking with SARS-CoV-2. And it is fantastic news that we have found a number of approved hepatitis C drugs as promising candidates for treatment."

Using the MOGON II supercomputer, the reseachers made more than 30 billion single calculations within two months and found that compounds from the four hepatitis C drugs simeprevir, paritaprevir, grazoprevir, and velpatasvir have a high affinity to bind SARS-CoV-2 very strongly and may therefore be able to prevent infection. "This is also supported by the fact that both SARS-CoV-2 and the hepatitis C virus are a virus of the same type, a so-called single-stranded RNA virus," explained Efferth. According to the researchers, a natural substance from the Japanese honeysuckle (Lonicera japonica), which has been used in Asia against various other diseases for some time now, might be another strong candidate against SARS-CoV-2.

"Our research results now need to be checked in laboratory experiments and clinical studies," said Efferth and added that molecular docking had already been used successfully in the search for active substances against the coronaviruses MERS-CoV and SARS-CoV.

Kadioglu O, Saeed M, Johannes Greten H, Efferth T.
Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning.
Bull World Health Organ. E-pub: 21 March 2020. doi: 10.2471/BLT.20.255943

Most Popular Now

Deep Learning Model Helps Detect Lung Tu…

A new deep learning model shows promise in detecting and segmenting lung tumors, according to a study published in Radiology, a journal of the Radiological Society of North America (RSNA)...

One of the Largest Global Surveys of Soc…

As leaders gather for the World Economic Forum Annual Meeting 2025 in Davos, Leaps by Bayer, the impact investing arm of Bayer, and Boston Consulting Group (BCG) announced the launch...

New Study Reveals AI's Transformati…

Intensive care units (ICUs) face mounting pressure to effectively manage resources while delivering optimal patient care. Groundbreaking research published in the INFORMS journal Information Systems Research highlights how a novel...

Sam Neville Joins the Highland Marketing…

Leading chief nursing information officer Sam Neville is joining the Highland Marketing advisory board. Sam brings a passion for nursing and safety to the board, which debates the big issues...

New Biomarkers to Detect Colorectal Canc…

Machine learning and artificial intelligence (AI) techniques and analysis of large datasets have helped University of Birmingham researchers to discover proteins that have strong predictive potential for colorectal cancer. In a...

AI Tool that may Assist Underserved Hosp…

As the fields of healthcare and technology increasingly evolve and intersect, researchers are collaborating on the best ways to use emerging technologies such as artificial intelligence (AI) to care for...

AI Model Identifies Potential Risk Genes…

Researchers from the Cleveland Clinic Genome Center have successfully applied advanced artificial intelligence (AI) genetics models to Parkinson's disease. Researchers identified genetic factors in progression and FDA-approved drugs that can...

AI-Supported Breast Cancer Screening - N…

The new findings are published in The Lancet Digital Health. The initial results of the Mammography Screening with Artificial Intelligence (MASAI) study* - a randomised trial to evaluate whether AI...

AI Improves Personalized Cancer Treatmen…

Personalized medicine aims to tailor treatments to individual patients. Until now, this has been done using a small number of parameters to predict the course of a disease. However, these...

The Future of Healthcare is Digital

8 - 10 April 2025, Berlin, Germany. The Berlin Exhibition Centre will be all about digital health from 8 to 10 April 2025. DMEA, Europe's leading event for digital healthcare, organised...

DMEA nova Award: Looking for the Best Id…

8 - 10 April 2025, Berlin, Germany. Innovative startups from the digital health sector can now apply for the DMEA nova Award 2025. We are looking for the best idea or...

Stanford Medicine Study Suggests Physici…

Artificial intelligence-powered chatbots are getting pretty good at diagnosing some diseases, even when they are complex. But how do chatbots do when guiding treatment and care after the diagnosis? For...